Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C

Journal of Hepatology

Volumn 51, Issue 1, 2009, Pages 21-28

  Neumann, Avidan U ^a   Pianko, Stephen ^b   Zeuzem, Stefan ^c   Yoshida, Eric M ^d   Benhamou, Yves ^e   Mishan, Moshe ^a   McHutchison, John G ^f   Pulkstenis, Erik ^g   Mani Subramanian, G ^g  

^a BAR ILAN UNIVERSITY   (Israel)

^b MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^g GLAXOSMITHKLINE   (United States)

Author keywords

albIFN; Albinterferon alfa 2b; CHC; Chronic hepatitis C; HCV; Hepatitis C virus; Peginterferon; Sustained virologic response; SVR

Indexed keywords

ALBINTERFERON ALPHA2B; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ALGORITHM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POPULATION RECOVERY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ALBUMINS; ALGORITHMS; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RNA, VIRAL;

EID: 67349192150     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.01.017     Document Type: Article

References (16)

1. Shepard C.W., Finelli L., and Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5 (2005) 558-567
2. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales Jr. F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
3. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
4. Patel K., Muir A.J., and McHutchison J.G. Diagnosis and treatment of chronic hepatitis C infection. BMJ 332 (2006) 1013-1017
5. Davis G.L., Wong J.B., McHutchison J.G., Manns M.P., Harvey J., and Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38 (2003) 645-652
6. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?. Ann Intern Med 140 (2004) 370-381
7. Ferenci P., Fried M.W., Shiffman M.L., Smith C.I., Marinos G., Gonçales Jr. F.L., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43 (2005) 425-433
8. Carlsson T., Reichard O., Norkrans G., Bläckberg J., Sangfelt P., Wallmark E., et al. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepat 12 (2005) 473-480
9. Jensen D.M., Morgan T.R., Marcellin P., Pockros P.J., Reddy K.R., Hadziyannis S.J., et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 43 (2006) 954-960
10. Marti{dotless}́nez-Bauer E., Crespo J., Romero-Gómez M., Moreno-Otero R., Solá R., Tesei N., et al. Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. Hepatology 43 (2006) 72-80
11. Yu J.W., Wang G.Q., Sun L.J., Li X.G., and Li S.C. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 22 (2007) 832-836
12. Subramanian G.M., Fiscella M., Lamousé-Smith A., Zeuzem S., and McHutchison J.G. Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 25 (2007) 1411-1419
13. Zeuzem S., Yoshida E.M., Benhamou Y., Pianko S., Bain V.G., Shouval D., et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology 48 (2008) 407-417
14. Colombatto P., Ciccorossi P., Maina A.M., Civitano L., Oliveri F., Coco B., et al. Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells. Clin Pharmacol Ther 84 (2008) 212-215
15. Conjeevaram H.S., Fried M.W., Jeffers L.J., Terrault N.A., Wiley-Lucas T.E., Afdhal N., et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131 (2006) 470-477
16. Zeuzem S., Pawlotsky J.M., Lukasiewicz E., von Wagner M., Goulis I., Lurie Y., et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 43 (2005) 250-257